🧪
hypothesis

TGF-β1–SMAD2/3 Axis as Master Suppressor of Microglial Trained Immunity

Hypothesis

TGF-β1–SMAD2/3 Axis as Master Suppressor of Microglial Trained Immunity

Astrocyte-derived TGF-β1 engages microglial TGFBRII/TGFBRI complex, activating SMAD2/3 corepressor complexes that displace RelA/p300 coactivators at NF-κB-dependent promoters (TNF, IL1B, IL6).
🧬 TGFBR1/TGFBR2 → SMAD4 → SMAD2/3🩺 neuroinflammation🎯 Composite 71%💱 $0.63▼20.1%proposed
EvidencePending (0%)📖 0 cit🗣 1 debates 4 support 3 oppose
✓ All Quality Gates Passed
Mechanistic 0.65 (15%) Evidence 0.78 (15%) Novelty 0.62 (12%) Feasibility 0.68 (12%) Impact 0.72 (12%) Druggability 0.71 (10%) Safety 0.45 (8%) Competition 0.70 (6%) Data Avail. 0.82 (5%) Reproducible 0.75 (5%) KG Connect 0.50 (8%) 0.712 composite
☰ Compare⚔️ Duel⚛️ Collide
📄 Export LaTeX
arXiv PreprintNeurIPSNature MethodsPLOS ONE
📖 Export BibTeXinteract with this hypothesis
Composite71%

🧪 Overview

Astrocyte-derived TGF-β1 engages microglial TGFBRII/TGFBRI complex, activating SMAD2/3 corepressor complexes that displace RelA/p300 coactivators at NF-κB-dependent promoters (TNF, IL1B, IL6). This mechanism rewires trained microglia to a homeostatic state by disrupting epigenetic memory at inflammatory gene enhancers. Supported by landmark ALS and Parkinson's disease studies showing TGF-β-driven anti-inflammatory microglial phenotypes.

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

flowchart TD
    A["Astrocyte-Derived TGF-beta1<br/>Anti-inflammatory Ligand"]
    B["TGFBR2/TGFBR1 Complex<br/>Microglial Receptor Activation"]
    C["SMAD2/3 Phosphorylation<br/>SMAD4 Corepressor Assembly"]
    D["RelA/p300 Displacement<br/>NF-kB Enhancer Rewiring"]
    E["TNF/IL1B/IL6 Suppression<br/>Trained Immunity Memory Reset"]
    F["Homeostatic Microglial State<br/>Inflammatory Tone Reduced"]
    A --> B
    B --> C
    C --> D
    D --> E
    E --> F
    style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
    style D fill:#7b1fa2,stroke:#ce93d8,color:#ce93d8
    style F fill:#1b5e20,stroke:#81c784,color:#81c784

⚖️ Evidence

⚖️ Evidence Matrix4 supports3 contradicts
Supports
TGF-β as key astrocyte-derived factor promoting anti-inflammatory microglial phenotype in ALS
PMID:30643267
Supports
Astrocytes release neuroprotective factors including TGF-β in reactive states
PMID:31983687
Supports
TGF-β1 suppresses microglial NLRP3 inflammasome in Parkinson's models
PMID:31748796
Supports
Reduced TGF-β signaling in Alzheimer's post-mortem microglia correlates with disease severity (AMP-AD)
PMID:公开数据库
Contradicts
TGF-β1 can maintain microglial activation in certain contexts; effects are dose- and context-dependent
PMID:30299354
Contradicts
TGF-β receptor signaling may suppress homeostatic surveillance (CX3CR1 downregulation), increasing infection vulnerability
PMID:32493736
Contradicts
SMAD2/3 binding sites are sparse at classical trained enhancer loci (TNF, IL6)
PMID:31628103
📖 Linked Papers

No linked papers recorded for this hypothesis yet.

🏥 Translation

🧬 3D Protein Structure — TGFBR1

No curated PDB or AlphaFold mapping for TGFBR1 yet. Search RCSB →

🧠 GTEx v10 Brain ExpressionJSON

Median TPM across 13 brain regions for TGFBR1/TGFBR2 → SMAD4 → SMAD2/3 from GTEx v10.

Cerebellar Hemisphere16.2 Cerebellum13.6 Spinal cord cervical c-111.6 Substantia nigra7.1 Hypothalamus5.8 Caudate basal ganglia3.8 Hippocampus3.6 Amygdala3.6 Nucleus accumbens basal ganglia3.2 Frontal Cortex BA93.2 Putamen basal ganglia3.1 Anterior cingulate cortex BA242.8 Cortex2.5median TPM (GTEx v10)

💉 Clinical Trials

No clinical trials data linked to this hypothesis yet.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for TGFBR1 →

No DepMap CRISPR Chronos data found for TGFBR1.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
Falling
7d Momentum
▼ 1.8%
Volatility
Medium
0.0352
Events (7d)
3
Price History
▼20.1%

💾 Resource Usage

LLM Tokens
13,698
$0.0411
Total Cost
$0.0411

🔮 Predictions

🔎 Predictions vs Observations2 predictions · 0 with recorded observations
PredictionPredictedObservedStatusConf
IF microglial SMAD2/3 is genetically ablated (Cx3cr1-CreER × Smad2/3 flox/flox) prior to TGF-β1 preconditioning, THEN the expected suppression of LPS-induced TNF-α, IL-1β, and IL-6 release will be aboTGF-β1 preconditioning fails to suppress inflammatory cytokine release in SMAD2/3-deficient microglia; cytokine levels remain elevated (TNF-α >500 pg/mL, IL-1β — no observation —pending0.70
IF CRISPR-mediated epigenetic blockade (dCas9-KRAB) prevents TGF-β1–induced H3K27ac reduction at the TNF, IL1B, and IL6 enhancer loci, THEN the anti-inflammatory reprogramming effect of TGF-β1 will beLoss of H3K27ac depletion at inflammatory gene enhancers preserves trained immunity phenotype; CRISPR-targeted microglia show TNF-α, IL-1β, and IL-6 release com— no observation —pending0.65
🔮 Falsifiable Predictions (2)
pendingconf 70%
IF microglial SMAD2/3 is genetically ablated (Cx3cr1-CreER × Smad2/3 flox/flox) prior to TGF-β1 preconditioning, THEN the expected suppression of LPS-induced TNF-α, IL-1β, and IL-6 release will be abolished (i.e., cytokine levels will not differ by >30% from vehicle-preconditioned controls) within 4
Predicted outcome: TGF-β1 preconditioning fails to suppress inflammatory cytokine release in SMAD2/3-deficient microglia; cytokine levels remain elevated (TNF-α >500 pg/
Falsification: TGF-β1 continues to suppress cytokine release by >50% despite SMAD2/3 deletion, indicating redundant or SMAD-independent anti-inflammatory pathways that would refute SMAD2/3 as the master suppressor.
pendingconf 65%
IF CRISPR-mediated epigenetic blockade (dCas9-KRAB) prevents TGF-β1–induced H3K27ac reduction at the TNF, IL1B, and IL6 enhancer loci, THEN the anti-inflammatory reprogramming effect of TGF-β1 will be abrogated, with trained microglia retaining inflammatory hyper-responsiveness (cytokine release >70
Predicted outcome: Loss of H3K27ac depletion at inflammatory gene enhancers preserves trained immunity phenotype; CRISPR-targeted microglia show TNF-α, IL-1β, and IL-6 r
Falsification: TGF-β1 still suppresses microglial inflammation even when H3K27ac marks are artificially maintained at NF-κB target enhancers, indicating that enhancer decommissioning is not the causal mechanism and
View on SciDEX ↗